Yuk Kam completed her Ph.D at The Chinese University of Hong Kong, with a research focus on the evaluation of efficacy and safety of fecal microbiota transplantation. She is experienced in clinical trials and epidemiological analyses.
Yuk Kam joined the Department of Family Medicine and Primary Care at HKU in November 2023, and is pursuing her interests in 1) health and health service research; 2) epidemiology in chronic diseases including diabetes and hypertension.
Key Publications
- Yau YK, Lau LHS, Lui RNS, Wong SH, Guo CL, Mak JWY, Ching JYL, Ip M, Kamm MA, Rubin DT, Chan PKS, Chan FKL, Ng SC. Long-term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data over Eight Years from the Hong Kong FMT Registry. Clin Gastroenterol Hepatol. 2023 Sep 19:S1542-3565(23)00712-7. doi: 10.1016/j.cgh.2023.09.001.
- Yau YK*, Su Q*, Xu Z, Tang W, Ching JYL, Mak JWY, Cheung CP, Fung M, Ip M, Chan FKL, Wu JCY, Ng SC.. Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2023; 00: 1–10. (* these authors contributed equally to the completion of this work)
- Yau YK, Mak WYJ, Lui NSR, Ng WYR, Cheung CYK, Li YLA, Ching YLJ, Chin ML, Lau HSL, Chan KLF, Chan KSP, Ng SC. High prevalence of extended-spectrum beta-lactamase organisms and the COVID-19 pandemic impact on donor recruitment for fecal microbiota transplantation in Hong Kong. United European Gastroenterol J. 2021
